CFLT Confluent, Inc. Insider Trading

CFO Sivaram Rohan sold 29,996 shares at $30.67, near 52-week high; 3 of 4 prior CFLT sales were well-timed

Sivaram Rohan, CFO of Confluent, Inc., sold 29,996 shares on 2026-03-12 at $30.67, reducing his holdings by 5.3% to 531,971 shares. The sale occurred at a price only -0.4% below the 52-week high of $30.79, suggesting timing near a peak. His prior trade history at Confluent shows a pattern of discipline: 3 of 4 prior measurable sales resulted in the stock declining within 90 days, indicating well-timed exits. However, the company remains unprofitable with a net income of $-66,504,000.00 in the latest quarter, despite revenue growth of 21.1% year-over-year. The convergence of near-peak pricing with a demonstrated ability to exit ahead of declines warrants monitoring, particularly given the company's profitability challenges.

CEO Edward Jay Kreps sold 270.2K shares of CFLT at $30.70 on 2026-02-20, reducing holdings by 47.2%, leaving 301.7K shares

Edward Jay Kreps, CEO of Confluent, sold 270.2K shares for $8.3M, reducing his equity stake by nearly half from 571.9K to 301.7K shares. This is a material reduction in CEO exposure to the company. Prior to this sale, Kreps executed five trades at CFLT over a three-month window (late November to mid-December 2025), all sells; the two December transactions show modest 30-day gains (1.1% and 1.6%) with outcomes not yet measurable at 90 days, while the three November sales posted strong 30-day and 90-day gains (27.7%–37.2%), indicating the stock rallied after those sales—a pattern inconsistent with well-timed selling. Confluent remains unprofitable ($-66.5M net income on $298.5M annual revenue growth of 21.1%), and at $30.70 the stock trades 7.8% below its 52-week high, suggesting the CEO is selling during a period of sideways-to-declining momentum following earlier strength. The frequency and scale of disposals warrants scrutiny into cash-needs versus conviction.

CRO Ryan Norris sells 31,273 shares across 2 transactions (Feb 20–24) for $959,290.86; follows bullish 90-day rally (+40.3%)

Ryan Norris, Chief Revenue Officer, executed 2 separate sales totaling 31,273 shares for $959,290.86, reducing his holdings by 8.0%. The sales occurred on 2026-02-20 at $30.70 and 2026-02-24 at $30.66, near current price ($30.62) and well within the 52-week range ($15.91–$33.23). His prior trades at CFLT show strong timing: 2 of 2 prior sales were well-timed at the 90-day mark, and the stock has rallied 40.3% over the past 90 days. However, the company remains unprofitable (full-year net income $-66,504,000.00) despite solid revenue growth of 21.1% year-over-year. The sale represents a modest reduction relative to his remaining post-transaction holdings (358,890 shares), and the timing relative to the recent 90-day bull run raises questions about conviction near recent highs.

CFO Sivaram Rohan sells 21,503 shares of CFLT at $30.70; stock now at $30.62. 4 of 5 prior CFLT sales were well-timed.

Sivaram Rohan, CFO of Confluent, sold 21,503 shares at $30.70 on 2026-02-20, reducing his holdings by -3.7% to 562.0K shares. At his prior five CFLT sales, he demonstrated a 80% well-timed rate at the 90-day mark (4 of 5 sells preceded declines), suggesting consistency in sale execution at this company. The current stock price of $30.62 is -7.8% from the 52-week high of $33.23, and the 90-day return since this sale is +40.3%, indicating the stock has risen sharply post-transaction. Confluent remains unprofitable (net income $-66.5M in the latest quarter) despite revenue growth of +21.1% year-over-year, which creates a backdrop of execution risk even as the recent momentum has been positive.

Director Narkhede sells 80,000 CFLT shares ($2.4M) at $30.59; retains 28.5K shares post-transaction

Director Neha Narkhede sold 80,000 shares of Confluent (CFLT) at $30.59 on 2026-02-13, reducing her holdings by -73.7% from 108.5K to 28.5K shares. The current price of $30.66 is -15.4% below the 52-week high of $36.23, and over the past 90 days the stock has advanced +42.5%. Narkhede's cross-ticker track record shows a 90d well-timed rate of 88.89% across 10 prior sales (negative post-sale returns), but at CFLT specifically, outcomes are more mixed: of 4 measurable prior sales, 3 were well-timed at 90-day mark (stock declined after), but one (2025-09-09) posted a +50.5% 90d return, indicating the stock rose sharply after that sale. This filing contains a derivative conversion; her post-transaction holdings in Table I do not represent her total position. Confluent remains unprofitable with FY net income of $-66.5M against $298.5M in latest quarterly revenue and +21.1% annual growth, creating a context of execution risk in a still-loss-making growth company.

Director Eric Vishria sold 61.9K CFLT shares at $30.57; stock +42.5% over 90 days vs mixed prior timing at ticker

Director Eric Vishria sold 61,905 shares of Confluent at $30.57, reducing holdings by 8.5% to 663,637 shares. The company remains unprofitable with net income of $-66,504,000.00 against quarterly revenue of $298,524,000.00, though annual growth reached +21.1%. His prior five trades at CFLT show mixed timing outcomes: two 2025 sales preceded substantial 90-day declines (returns of -34.4% and -35.4%), but three 2024 sales saw positive 90-day returns (+13.7% to +18.9%), suggesting inconsistent predictive value at this ticker. With the stock up +42.5% over the past 90 days and currently trading -15.4% below its 52-week high of $36.23, this sale occurs within a strong rally phase, distinct from the downturns that followed his earlier 2025 sales.

CEO Kreps sells 738,500 shares ($22.2M) across 2 tranches; stock up 28.6% (30d), 53.0% (90d)

Edward Jay Kreps, CEO of Confluent, executed 2 separate sales totaling 738,500 shares for $22,198,490.00, reducing his holdings from 1,077,867 shares to 339,367 shares (a -68.5% reduction in position). The transaction occurred at a blended average price of $30.06, while the current stock price stands at $29.96—less than 1% below execution price. This follows a period of strong momentum: the stock is up 28.6% over the past 30 days and up 53.0% over 90 days, though it remains 20.4% below its 52-week high of $37.65. At same-ticker level, Kreps' prior two measurable sales at CFLT (from late August and early September) were poorly timed, with positive returns of 8.8% and 17.7% at 30 days (indicating the stock rose after he sold). The company reported a net loss of $66,504,000 for its latest fiscal year despite revenue growth of 24.0%, presenting mixed operational fundamentals. The timing of this sale during a significant rally warrants attention to whether it reflects an internal assessment of current valuation relative to fundamentals.

Director Henry Alyssa sold 62,500 shares of CFLT at $30.00 (total $1.9M), reducing stake to 28.5K shares; stock up 56.2% in 90 days from loss-making company.

Director Henry Alyssa sold 62,500 shares at $30.00 on 2025-12-10, reducing her direct holdings from 91,049 shares to 28,549 shares—a 68.6% reduction in that specific batch. However, a DERIVATIVE-CONVERSION flag indicates she holds additional securities in Table II (derivative holdings) not yet populated in the database, so this sale should not be read as a near-complete exit from Confluent. The sale occurs after the stock has appreciated significantly: up 56.2% over 90 days and up 23.4% over 30 days, though it remains 20.2% below the 52-week high of $37.65. Confluent remains unprofitable (net income of $-66.5M in the latest fiscal year) despite strong revenue growth of 24.0% year-over-year. The large absolute value of the sale ($1.9M) against continued losses suggests the director liquidated a substantial portion of her direct equity stake, though her derivative position status warrants clarification to assess her net exposure.

CRO Ryan Norris sold 44,114 shares of CFLT at $29.77; repeat seller with 100% well-timed 90-day sell pattern.

Ryan Norris, Chief Revenue Officer, sold 44,114 shares (11.6% of pre-transaction holdings) at $29.77 on 2025-12-08 for $1,313,273.78. His prior two open-market sales at CFLT on 2025-05-22 and 2025-05-20 both exhibited negative 90-day returns (-19.3% and -18.1% respectively), and across his broader cross-ticker trading history, his 90-day well-timed rate stands at 100.00%, meaning his sells consistently preceded subsequent declines. The current share price of $30.00 is 20.3% below the 52-week high of $37.65, while the stock has risen 27.5% over the last 30 days and 54.2% over 90 days, contrasting sharply with his historical pattern of selling before downturns. Confluent's fundamentals show persistent unprofitability (net income of -$66.5M against $298.5M in quarterly revenue) despite strong 24.0% annual revenue growth, presenting a risk-reward asymmetry that may be driving his repeat disposal of shares.

Director Narkhede sells 40,000 CFLT shares at $29.77; prior 5 trades at this ticker show 4 of 5 were well-timed (negative 90d returns).

Director Neha Narkhede sold 40,000 shares of Confluent at $29.77 on 2025-12-08, reducing her stake by 58.4%. Her prior trade history at this ticker reveals a strong timing pattern: 4 of 5 prior sells occurred before periods of stock declines, with 90-day returns of +21.3%, +15.4%, -19.0%, -22.4%, and -24.0%—indicating most recent trades were positioned ahead of weakness. The stock is currently priced at $30.00, down 20.3% from its 52-week high of $37.65, and has risen 27.5% over the past 30 days and 54.2% over 90 days, suggesting a recent recovery phase. Confluence operates with negative net income of $-66,504,000.00 in the latest quarter despite 24.0% annual revenue growth, pointing to profitability challenges. The scale of this 40,000-share reduction, combined with the insider's demonstrated ability to time prior exits at this ticker ahead of downturns, merits close attention to forward guidance and unit economics.